Načítá se...
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
The therapeutic targeting of the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis marked a milestone in the treatment of non-small cell lung cancer (NSCLC), leading to unprecedented response duration and long-term survival for a relevant subgroup of patients affected by non-oncogene-...
Uloženo v:
| Vydáno v: | Immunotargets Ther |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7872895/ https://ncbi.nlm.nih.gov/pubmed/33575224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S253581 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|